Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -2.97% is 117% below its 5-year average of 17.70%, near the low end of its 5-year range (-2.97%–31.02%).
As of the fiscal period ended Tuesday, June 30, 2026. 6154.37% below its 12-month average of -0.05%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -2.97%.
RETURN ON EQUITY (ROE)
-2.97%
RETURN ON EQUITY (ROE) AVG TTM
-0.05%
RETURN ON EQUITY (ROE) AVG 3Y
12.21%
RETURN ON EQUITY (ROE) AVG 5Y
17.70%
RETURN ON EQUITY (ROE) AVG 10Y
17.99%
RETURN ON EQUITY (ROE) AVG 15Y
15.74%
RETURN ON EQUITY (ROE) AVG 20Y
15.53%
CURRENT VS TTM AVG
-6154.37%
CURRENT VS 3Y AVG
-124.29%
CURRENT VS 5Y AVG
-116.76%
CURRENT VS 10Y AVG
-116.49%
CURRENT VS 15Y AVG
-118.85%
CURRENT VS 20Y AVG
-119.10%
SECTOR MEDIAN · HEALTHCARE
-40.30%
median of 604 covered companies
CURRENT VS SECTOR MEDIAN
+92.64%
vs the sector median at left
Bruker Corporation
Market Cap
$9.30B
Return on Equity (ROE)
-2.97%
TTM Avg
-0.05%
3Y Avg
12.21%
5Y Avg
17.70%
Market Cap
$9.40B
Return on Equity (ROE)
26.39%
TTM Avg
25.41%
3Y Avg
19.99%
5Y Avg
14.02%
Market Cap
$9.00B
Return on Equity (ROE)
9.85%
TTM Avg
9.79%
3Y Avg
-15.74%
5Y Avg
-21.41%
Market Cap
$8.99B
Return on Equity (ROE)
-230.05%
TTM Avg
-355.61%
3Y Avg
-251.82%
5Y Avg
-322.00%
Market Cap
$8.98B
Return on Equity (ROE)
-2.97%
TTM Avg
3.00%
3Y Avg
15.91%
5Y Avg
17.66%
Market Cap
$9.70B
Return on Equity (ROE)
-38.59%
TTM Avg
-21.29%
3Y Avg
-24.61%
5Y Avg
-26.58%
Market Cap
$9.74B
Return on Equity (ROE)
12.77%
TTM Avg
11.88%
3Y Avg
12.69%
5Y Avg
13.50%
Market Cap
$9.75B
Return on Equity (ROE)
17.77%
TTM Avg
13.11%
3Y Avg
0.20%
5Y Avg
-3.65%
Market Cap
$8.80B
Return on Equity (ROE)
-68.73%
TTM Avg
-161.81%
3Y Avg
-110.86%
5Y Avg
-82.70%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bruker Corporation (BRKR) | $9.30B | -2.97% | -0.05% | 12.21% | 17.70% |
| Insulet Corp. (PODD)vs › | $9.40B | 26.39% | 25.41% | 19.99% | 14.02% |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $9.00B | 9.85% | 9.79% | -15.74% | -21.41% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.99B | -230.05% | -355.61% | -251.82% | -322.00% |
| Bruker Corporation (BRKRP)vs › | $8.98B | -2.97% | 3.00% | 15.91% | 17.66% |
| Vaxcyte, Inc. (PCVX)vs › | $9.70B | -38.59% | -21.29% | -24.61% | -26.58% |
| Henry Schein, Inc. (HSIC)vs › | $9.74B | 12.77% | 11.88% | 12.69% | 13.50% |
| Krystal Biotech, Inc. (KRYS)vs › | $9.75B | 17.77% | 13.11% | 0.20% | -3.65% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.80B | -68.73% | -161.81% | -110.86% | -82.70% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.75B | -19.85% | -23.25% | -28.82% | -25.53% |
ROE
-3.0%
ROA
-1.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -2.97% |
| 2026-03-31 | -0.47% |
| 2025-12-31 | -0.35% |
| 2025-09-30 | -0.86% |
| 2025-06-30 | 4.41% |
| 2025-03-31 | 4.38% |
| 2024-12-31 | 6.35% |
| 2024-09-30 | 16.87% |
| 2024-06-30 | 19.68% |
| 2024-03-31 | 28.38% |
| 2023-12-31 | 31.02% |
| 2023-09-30 | 26.40% |
| 2023-06-30 | 25.92% |
| 2023-03-31 | 26.39% |
| 2022-12-31 | 26.63% |
| 2022-09-30 | 29.34% |
| 2022-06-30 | 28.22% |
| 2022-03-31 | 27.73% |
| 2021-12-31 | 25.89% |
| 2021-09-30 | 25.13% |
| 2021-06-30 | 23.70% |
| 2021-03-31 | 21.08% |
| 2020-12-31 | 16.42% |
| 2020-09-30 | 16.54% |
| 2020-06-30 | 18.33% |
| 2020-03-31 | 19.32% |
| 2019-12-31 | 21.75% |
| 2019-09-30 | 24.18% |
| 2019-06-30 | 21.70% |
| 2019-03-31 | 19.91% |
| 2018-12-31 | 19.85% |
| 2018-09-30 | 11.90% |
| 2018-06-30 | 11.69% |
| 2018-03-31 | 10.63% |
| 2017-12-31 | 10.72% |
| 2017-09-30 | 20.41% |
| 2017-06-30 | 21.03% |
| 2017-03-31 | 20.72% |
| 2016-12-31 | 22.16% |
| 2016-09-30 | 20.83% |
| 2016-06-30 | 16.60% |
| 2016-03-31 | 16.74% |
| 2015-12-31 | 13.86% |
| 2015-09-30 | 8.63% |
| 2015-06-30 | 7.82% |
| 2015-03-31 | 7.55% |
| 2014-12-31 | 7.35% |
| 2014-09-30 | 8.09% |
| 2014-06-30 | 8.69% |
| 2014-03-31 | 9.60% |
| 2013-12-31 | 9.42% |
| 2013-09-30 | 7.42% |
| 2013-06-30 | 11.23% |
| 2013-03-31 | 9.83% |
| 2012-12-31 | 10.97% |
| 2012-09-30 | 14.98% |
| 2012-06-30 | 13.08% |
| 2012-03-31 | 14.51% |
| 2011-12-31 | 14.85% |
| 2011-09-30 | 13.68% |
| 2011-06-30 | 14.28% |
| 2011-03-31 | 15.85% |
| 2010-12-31 | 18.18% |
| 2010-09-30 | 22.19% |
| 2010-06-30 | 23.90% |
| 2010-03-31 | 21.27% |
| 2009-12-31 | 19.42% |
| 2009-09-30 | 17.02% |
| 2009-06-30 | 19.30% |
| 2009-03-31 | 24.83% |
| 2008-12-31 | 20.80% |
| 2008-09-30 | 17.95% |
| 2008-06-30 | 14.15% |
| 2008-03-31 | 9.31% |
| 2007-12-31 | 12.19% |
| 2007-09-30 | 11.41% |
| 2007-06-30 | 9.71% |
| 2007-03-31 | 7.94% |
| 2006-12-31 | 7.28% |
| 2006-09-30 | 3.46% |
| 2006-06-30 | 1.93% |
| 2006-03-31 | 1.89% |
| 2005-12-31 | 1.75% |
| 2005-09-30 | 0.15% |
| 2005-06-30 | -1.69% |
| 2005-03-31 | -3.98% |
| 2004-12-31 | -3.60% |
| 2004-09-30 | -2.90% |
| 2004-06-30 | -8.57% |
| 2004-03-31 | -6.75% |
| 2003-12-31 | -7.74% |
| 2003-09-30 | -10.57% |
| 2003-06-30 | -3.30% |
